GlassScriptPhysician profile
April Mcgriff
NPI 1861988735
$4,144.43
in general payments reported to CMS, 2019-2025
34 companies · $3,683 in 2025
The $3,683 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $309 · 2023: $16.37 · 2025: $3,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,628 · Travel and Lodging: $988 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,627.99 |
| Travel and Lodging | $987.55 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,077.10 | 2025 | Vercise, General - Dbs |
| Abbott Laboratories | $489.22 | 2025 | Infinity, Proclaim |
| Abbvie INC. | $406.11 | 2025 | |
| Janssen Biotech, INC. | $218.35 | 2025 | |
| Sk Life Science, INC. | $185.87 | 2025 | |
| Lilly USA, LLC | $173.97 | 2025 | Kisunla, Amyvid |
| Biogen, INC. | $135.95 | 2025 | Vumerity, Tysabri, Leqembi |
| Galderma Laboratories, L.P. | $125.00 | 2022 | |
| Smith+Nephew, INC. | $121.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $119.64 | 2021 | |
| Novo Nordisk INC | $106.52 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $94.82 | 2021-2023 | |
| Ucb, INC. | $83.53 | 2025 | Briviact |
| Axsome Therapeutics, INC. | $76.82 | 2025 | Symbravo |
| Lundbeck LLC | $60.71 | 2025 | Vyepti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $56.02 | 2025 | |
| Celgene Corporation | $51.75 | 2025 | Zeposia |
| Neurocrine Biosciences, INC. | $46.84 | 2025 | |
| Vanda Pharmaceuticals INC. | $45.59 | 2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $45.46 | 2025 | Hyqvia |
| Genentech USA, INC. | $44.97 | 2025 | Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $42.25 | 2025 | Crexont |
| Pfizer INC. | $39.83 | 2025 | |
| Mdd US Operations, LLC | $37.21 | 2025 | Gocovri |
| Janssen Scientific Affairs, LLC | $37.14 | 2025 | Tecvayli, Darzalex, Carvykti |
| Eisai INC. | $34.76 | 2025 | |
| Octapharma USA, INC. | $31.96 | 2025 | Panzyga |
| Medtronic, INC. | $29.79 | 2025 | Percept PC Brainsense |
| Merz Pharmaceuticals, LLC | $24.52 | 2025 | Xeomin |
| Ge Healthcare | $24.11 | 2025 | |
| Livanova USA, INC. | $22.67 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Adc Therapeutics America, INC. | $20.52 | 2025 | |
| Supernus Pharmaceuticals, INC. | $19.38 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $14.24 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Mcgriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.